Hematologic Malignancy
Childhood Acute Myeloid Leukemia
CI-CAN-00004822Explore in graph →
PediatricHematologic15 active trials3 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004822Explore in graph →
Clinical trials
128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (19)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05313958 | Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children(SCCLG-M5) | unknown | Phase 2 / Phase 3 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT03825367 | Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 13 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 |
| Oct 12, 2022 |
| clinicaltrials |
| NCT02638428 | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | unknown | Phase 2 | 90 | Samsung Medical CenterOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT02848183 | Optimal Treatment Strategy Based on for Pediatric AML | unknown | Phase 2 | 350 | Samsung Medical CenterOTHER | 1 | Jul 28, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jul 27, 2023source: clinicaltrials